Clinical trialPhase 1 / Phase 2Recruiting
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Correlation With AKR1C3 Enzyme Expression of AST-001 in Subjects With Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 7 July 2022
- Expected end
- 31 August 2027
- Enrollment
- 180 participants
- Sites
- 1
- Primary outcomes
- Incidence and severity of adverse events (AEs); Assess safety changes in electrocardiogram (ECG); Assess safety changes of body weight.; Number of participants with dose limiting toxicities (DLTs); Define the Recommended Phase 2 Dose (RP2D)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 7 February 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.